The Filing Desk

Beam Therapeutics

BEAM · Nasdaq · Health Care · Financials, fiscal 2019 to 2025

BEAM · Last close · November 13, 2026
$22.83
Value Beam Therapeutics yourself

Beam Therapeutics' revenue rose 120.0% to $140 million in fiscal 2025. Its operating margin was −274.6%, up from −654.2% a year earlier. Free cash flow was −$360 million. The diluted share count rose 20.2%.

Beam Therapeutics Inc. Latest fiscal year ended December 31, 2025 10-K filed February 24, 2026 · 0001193125-26-065194 Updated
Revenue
$140M
120.0%
Operating margin
−274.6%
379.7 pts
Net income
−$80M
 
Free cash flow
−$360M
 
Return on equity
−8.1%
35.8 pts
Market cap
$2.4B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Interest coverage for fiscal 2025 is blank: the 10-K's structured data has no interest expense for that year.

Charts show fiscal years, from the 10-K filings.

What Beam Therapeutics does

Beam Therapeutics is a biotechnology company that develops gene-editing medicines. Its technology, called base editing, changes a single letter of DNA without cutting both strands of the DNA. The company also builds its own delivery technologies and has its own manufacturing. It has never sold a product.

Its lead program, risto-cel, is a treatment made from a patient's own stem cells to treat sickle cell disease. The company says it could file for approval as early as the end of 2026. Another program, BEAM-302, is a one-time treatment for alpha-1 antitrypsin deficiency, a genetic liver and lung disease. It also has programs for phenylketonuria and glycogen storage disease type 1a.

Beam has no product revenue and says it expects losses for the foreseeable future. It has a financing agreement with Sixth Street Lending Partners and says it will need more funding.

Its biggest risks, as it describes them

  • It has lost money since it began and may never be profitable.
  • It will need more funding, which could dilute shareholders or limit its operations.
  • It has never earned revenue from product sales.
  • Base editing is a new technology and may never lead to products it can sell.
  • Clinical trials may be delayed or fail, and early results may not predict later ones.
From Beam Therapeutics's annual report on Form 10-K, filed February 24, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Beam Therapeutics lost money in fiscal 2025: a net loss of $80 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments9661,1001,2008511,200
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage−692.2x−900.2x−1,103.0x−12,986.5x—
Current ratio6.0x4.9x5.9x4.8x13.1x
Quick ratio6.0x4.9x5.9x4.8x13.1x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Beam Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Beam Therapeutics shares on the open market, and 7 insiders sold $18.5 million, $8.5 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Jul 27, 2026Amy SimonChief Medical OfficerSold plan16,667$25.74$429,009Form 4
Jun 30, 2026John M. EvansCEO, DirectorSold plan25,000$34.30$857,602Form 4
Jun 30, 2026Amy SimonChief Medical OfficerSold plan373$34.73$12,954Form 4
Jun 29, 2026John M. EvansCEO, DirectorSold plan25,000$35.49$887,282Form 4
Jun 26, 2026Fmr Llc10% ownerSold251,488$35.26$8.9 millionForm 4
Jun 25, 2026Fmr Llc10% ownerSold33,372$35.12$1.2 millionForm 4
Apr 1, 2026John M. EvansCEO, DirectorSold plan30,078$24.58$739,317Form 4
Apr 1, 2026Giuseppe CiaramellaPresidentSold plan11,810$24.58$290,290Form 4
Apr 1, 2026Amy SimonChief Medical OfficerSold plan6,700$24.58$164,686Form 4
Apr 1, 2026Christine BellonChief Legal OfficerSold plan5,956$24.58$146,398Form 4
Apr 1, 2026Bethany J CavanaghSVP, Finance and TreasurerSold plan3,242$24.58$79,688Form 4
Mar 31, 2026John M. EvansCEO, DirectorSold plan25,000$22.76$569,000Form 4
The latest 12 of 22 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40471.6%−644.0%−137.6%
Altman Z''3.20−0.945.19
Accruals ratio1.2%−2.3%20.5%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassFailPass
Cash from operations exceeds net incomeFailPassFail
Debt fell relative to assets———
Current ratio rosePassFailPass
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassFailPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Beam Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Beam TherapeuticsFY25120.0%−274.6%−257.6%———
XencorFY2513.7%−141.3%−110.1%−19.9%—3Compare
Monte Rosa TherapeuticsFY2563.5%−43.8%−22.2%———Compare
RegenxbioFY25104.5%−94.6%−74.2%———Compare
ImmunityBioFY25668.3%−226.0%−272.6%——3Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

7 years of figures

Fiscal yearFY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue00526137864140
Revenue growth—33.3%215,916.7%17.5%520.0%−83.2%120.0%
Gross profit———————
Research and development55103387312437368410
Operating income−75−133−392−338−176−416−384
Net income−78−195−371−289−132−377−80
Diluted EPS (US$)−14.05−4.19−5.77−4.13−1.72−4.58−0.81
Diluted shares (millions)6476470778299
Cash flow
Cash from operations−72−96−6622−149−347−345
Capital expenditure1216474934915
Free cash flow−85−112−113−26−183−356−360
Dividends paid0000000
Share buybacks0000000
Acquisitions0000000
Stock-based compensation71544849912194
Balance sheet at fiscal year end
Cash and short-term investments373009661,1001,2008511,200
Debt incl. finance leases———————
Total assets1564521,4741,3421,4601,1041,481
Total liabilities55206648608478370243
Shareholders' equity−2012468277349817341,238
Margins and ratios
Gross margin———————
Operating margin−417,522.2%−553,166.7%−757.0%−555.6%−46.7%−654.2%−274.6%
Net margin−435,144.4%−810,800.0%−714.9%−474.5%−35.1%−593.1%−57.2%
Free cash flow margin−469,561.1%−467,075.0%−218.1%−43.4%−48.4%−560.8%−257.6%
Rule of 40 (growth + FCF margin)—−467,041.7%215,698.5%−25.9%471.6%−644.0%−137.6%
Return on capital———————
Return on equity—−875.4%−69.1%−37.1%−15.5%−43.9%−8.1%
Return on assets—−64.0%−38.5%−20.5%−9.5%−29.4%−6.2%
Net debt to EBITDA———————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Beam Therapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Beam Therapeutics.